Monogram OrthopaedicsMGRM
MGRM
About: Monogram Technologies Inc develops a product solution architecture to enable patient-optimized orthopedic implants at scale by linking 3D printing and robotics with pre-operative imaging. The company has a robot prototype that can autonomously execute optimized paths for high-precision insertion of implants in synthetic bone specimens. Monogram also intends to produce and market robotic surgical equipment and related software, orthopedic implants, tissue ablation tools, navigation consumables, and other miscellaneous instrumentation necessary for reconstructive joint replacement procedures.
Employees: 27
1
Funds holding %
of 7,407 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
1,100% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 1
150% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 4
31% more funds holding
Funds holding: 35 [Q3] → 46 (+11) [Q4]
1% more capital invested
Capital invested by funds: $3.5M [Q3] → $3.52M (+$20.1K) [Q4]
0.16% more ownership
Funds ownership: 4.16% [Q3] → 4.33% (+0.16%) [Q4]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$5.40
101%
upside
Avg. target
$5.40
101%
upside
High target
$5.40
101%
upside
1 analyst rating
1 positive
100%
0 neutral
0%
0 negative
0%
Roth MKM Jason Wittes 38% 1-year accuracy 8 / 21 met price target | 101%upside $5.40 | Buy Maintained | 18 Mar 2025 |
Financial journalist opinion
Neutral
Accesswire
4 weeks ago
Monogram Technologies Partners with Urvin to Launch an Exclusive, Verified Shareholder Community
AUSTIN, TX / ACCESS Newswire / March 20, 2025 / Monogram Technologies Inc. (NASDAQ:MGRM) ("Monogram" or the "Company"), an AI-driven robotics company focused on improving human health with an initial focus on orthopedic surgery, is pleased to announce its partnership with Urvin, a private, verified message board exclusively for active Monogram shareholders. This platform offers a way for shareholders to communicate directly with each other while providing Monogram with an additional tool to provide important company updates and reach the broadest possible shareholder audience.
Neutral
Accesswire
1 month ago
Monogram Technologies Announces FDA 510(k) Clearance for the Monogram mBôsTM TKA System
Monogram May Market the Monogram mBôs™ TKA System, Subject to the Requirements of the Federal Food, Drug, and Cosmetic Act (the Act). The Company is Preparing for Commercialization and Evaluating Strategies to Support the Adoption of its Robotic-Assisted Technology AUSTIN, TX / ACCESS Newswire / March 17, 2025 / Monogram Technologies Inc. (NASDAQ:MGRM) ("Monogram" or the "Company"), an AI-driven robotics company focused on improving human health with an initial focus on orthopedic surgery, today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for its Monogram mBôs™ TKA System.
Neutral
Seeking Alpha
1 month ago
Monogram Technologies Inc. (MGRM) Q4 2024 Earnings Call Transcript
Monogram Technologies Inc. (NASDAQ:MGRM ) Q4 2024 Earnings Conference Call March 11, 2025 4:30 PM ET Company Participants Larry Holub - Investor Relations Benjamin Sexson - Chief Executive Officer Noel Knape - Chief Financial Officer Conference Call Participants Jason Wittes - ROTH MKM Tom Kerr - Zacks Small-Cap Research Larry Holub Good afternoon everyone. I'm Larry Holub, Director at MZ North America, and would like to welcome you to the Monogram Technologies fourth quarter and full year 2024 financial results and business update conference call.
Neutral
Accesswire
1 month ago
CORRECTION: Monogram Technologies Reports Full Year 2024 Financial Results
This Press Release is Acting as a Correction to the Financial Tables in the Previous Release Completed all Supplemental Testing and has Submitted its Formal Response to the FDA's Additional Information Request (AIR) Management to Host Business Update Conference Call on Wednesday, March 12, 2025, at 4:30 p.m. Eastern Time AUSTIN, TEXAS / ACCESS Newswire / March 12, 2025 / Monogram Technologies Inc. (NASDAQ:MGRM) ("Monogram" or the "Company"), an AI-driven robotics company focused on improving human health with an initial focus on orthopedic surgery, has reported its financial and operational results for the fourth quarter and year ended December 31, 2024.
Neutral
Accesswire
1 month ago
Monogram Technologies Reports Full Year 2024 Financial Results
Completed all Supplemental Testing and has Submitted its Formal Response to the FDA's Additional Information Request (AIR) Management to Host Business Update Conference Call on Wednesday, March 12, 2025, at 4:30 p.m. Eastern Time AUSTIN, TX / ACCESS Newswire / March 12, 2025 / Monogram Technologies Inc. (NASDAQ:MGRM) ("Monogram" or the "Company"), an AI-driven robotics company focused on improving human health with an initial focus on orthopedic surgery, has reported its financial and operational results for the fourth quarter and year ended December 31, 2024.
Neutral
Accesswire
1 month ago
Monogram Technologies to Participate in the 37th Annual ROTH Conference in California March 16-18, 2025
AUSTIN, TX / ACCESS Newswire / March 5, 2025 / Monogram Technologies Inc. (NASDAQ:MGRM) ("Monogram" or the "Company"), an AI-driven robotics company focused on improving human health with an initial focus on orthopedic surgery, today announced that Chief Executive Officer Ben Sexson and Chief Financial Officer Noel Knape will participate in the 37th Annual ROTH Conference at the Laguna Cliffs Marriott Resort & Spa in Dana Point, CA March 16-18, 2025. Mr. Sexson and Mr.
Neutral
Accesswire
1 month ago
Monogram Technologies to Host Fourth Quarter and Full Year 2024 Results Conference Call on Wednesday, March 12, 2025 at 4:30 p.m. Eastern Time
AUSTIN, TX / ACCESS Newswire / February 27, 2025 / Monogram Technologies Inc. (NASDAQ:MGRM) ("Monogram" or the "Company"), an AI-driven robotics company focused on improving human health with an initial focus on orthopedic surgery, will hold a conference call webcast on Wednesday, March 12, 2025 at 4:30 p.m. Eastern Time in conjunction with its reported financial results for the fourth quarter and full fiscal year ended December 31, 2024, and to discuss regulatory updates and key milestones.
Neutral
Accesswire
1 month ago
Monogram Technologies Provides Regulatory Update on mBôs TKA System and Clinical Trial Preparation in India
Company has Completed all Supplemental Testing and has Submitted its Formal Response to the FDA's Additional Information Request (AIR) Investigator Meeting and Clinical Trial Training Held at the Shalby Hospital in Ahmedabad, India AUSTIN, TX / ACCESS Newswire / February 26, 2025 / Monogram Technologies Inc. (NASDAQ:MGRM) ("Monogram" or the "Company"), an AI-driven robotics company focused on improving human health with an initial focus on orthopedic surgery, today provided an update regarding its 510(k) premarket filing submission to the U.S. Food and Drug Administration ("FDA") for the Company's mBôs TKA System. The Company has completed all supplemental testing and submitted its formal response to the U.S. Food and Drug Administration (FDA) regarding the Additional Information Request (AIR) received on September 30, 2024.
Neutral
Accesswire
3 months ago
Monogram Technologies Provides 510(k) Submission Update Following Positive Meeting with FDA
Management Anticipates That it has Sufficiently Addressed the FDA's Concerns to Mitigate the Need for a Clinical Data Request Management Anticipates a Comprehensive AIR Response in Q1 2025 AUSTIN, TX / ACCESSWIRE / December 18, 2024 / Monogram Technologies Inc. (NASDAQ:MGRM) ("Monogram" or the "Company"), an AI-driven robotics company focused on improving human health with an initial focus on orthopedic surgery, today provided an update from its Submission Issue Request (SIR) meeting with the U.S. Food and Drug Administration ("FDA") on December 17, 2024, regarding its 510(k) premarket filing submission for the Company's mBôs TKA System (the "Application"). The Application was submitted on July 19, 2024, and passed the initial FDA Administrative Review.
Neutral
Seeking Alpha
4 months ago
Monogram Technologies Inc. (MGRM) Q3 2024 Earnings Call Transcript
Monogram Technologies Inc. (NASDAQ:MGRM ) Q3 2024 Earnings Call Transcript November 19, 2024 4:30 PM ET Company Participants Ben Sexson - CEO Noel Knape - CFO Larry Holub - IR Conference Call Participants Tom Kerr - Zacks Investment Research Operator Greetings and welcome to the Monogram Technologies Third Quarter 2024 Financial Results and Business Update Conference Call. At this time, all participants are in a listen-only mode.
Charts implemented using Lightweight Charts™